31,459 Shares in Incyte Corporation $INCY Bought by CPC Advisors LLC

Key Points

• CPC Advisors established a new position in Incyte by buying 31,459 shares in the fourth quarter, valued at roughly $3.11 million.
• Pablo J. Cagnoni, Incyte’s President & Global Head of R&D, sold 18,667 shares under a pre-arranged Rule 10b5-1 plan at an average price of $96.50 (~$1.8M), reducing his holding by about 6.6%, a move some traders view as a near-term negative signal.
• Incyte carries a market capitalization of about $19.2 billion and a PE of 15.0, recently missed quarterly EPS ($1.80 vs. $1.96) despite a revenue beat, and has a consensus analyst rating of Hold with a $104.89 target; pipeline positives like Phase 3 tafasitamab data and an Adagene collaboration could support future upside.

CPC Advisors LLC bought a new position in shares of Incyte Corporation (NASDAQ:INCY - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 31,459 shares of the biopharmaceutical company's stock, valued at approximately $3,107,000.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Bank of Nova Scotia increased its position in Incyte by 0.7% during the second quarter. Bank of Nova Scotia now owns 17,041 shares of the biopharmaceutical company's stock worth $1,160,000 after acquiring an additional 124 shares during the period. Atlantic Edge Private Wealth Management LLC increased its position in Incyte by 0.9% during the third quarter. Atlantic Edge Private Wealth Management LLC now owns 14,556 shares of the biopharmaceutical company's stock worth $1,235,000 after acquiring an additional 125 shares during the period. Perbak Capital Partners LLP increased its position in Incyte by 2.5% during the third quarter. Perbak Capital Partners LLP now owns 5,298 shares of the biopharmaceutical company's stock worth $449,000 after acquiring an additional 129 shares during the period. Savvy Advisors Inc. increased its position in Incyte by 2.6% during the fourth quarter. Savvy Advisors Inc. now owns 5,339 shares of the biopharmaceutical company's stock worth $527,000 after acquiring an additional 133 shares during the period. Finally, Haven Capital Group Inc. increased its position in Incyte by 0.8% during the fourth quarter. Haven Capital Group Inc. now owns 17,985 shares of the biopharmaceutical company's stock worth $1,776,000 after acquiring an additional 144 shares during the period. Institutional investors own 96.97% of the company's stock.

Insider Transactions at Incyte

In other Incyte news, insider Pablo J. Cagnoni sold 18,667 shares of the business's stock in a transaction on Friday, April 17th. The shares were sold at an average price of $96.50, for a total value of $1,801,365.50. Following the sale, the insider owned 262,692 shares of the company's stock, valued at $25,349,778. The trade was a 6.63% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.80% of the stock is owned by company insiders.

Incyte Trading Down 0.7%

Shares of Incyte stock opened at $96.22 on Wednesday. The firm has a market capitalization of $19.15 billion, a PE ratio of 15.01, a price-to-earnings-growth ratio of 0.77 and a beta of 0.85. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 3.25. The company's fifty day moving average price is $96.37 and its two-hundred day moving average price is $98.39. Incyte Corporation has a 52-week low of $56.77 and a 52-week high of $112.29.

Incyte (NASDAQ:INCY - Get Free Report) last announced its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.96 by ($0.16). The business had revenue of $1.51 billion during the quarter, compared to the consensus estimate of $1.35 billion. Incyte had a net margin of 25.03% and a return on equity of 26.34%. The company's quarterly revenue was up 27.8% compared to the same quarter last year. During the same period last year, the firm earned $1.43 EPS. On average, analysts expect that Incyte Corporation will post 6.55 EPS for the current year.

Key Stories Impacting Incyte

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Incyte highlighted new Phase 3 tafasitamab data at the 2026 ASCO meeting, which could support future approval/label expansion and longer-term revenue upside for its oncology franchise. ASCO Tafasitamab Data
• Positive Sentiment: Incyte entered a collaboration with Adagene to evaluate a combo therapy for colorectal cancer, broadening its clinical pipeline and partnership optionality in immuno-oncology. Adagene Partnership
• Positive Sentiment: Analysts and outlets continue to flag Incyte as a value play given recent pullbacks versus fundamentals, which may attract value-focused buyers over time. Value Stock Note
• Neutral Sentiment: RBC Capital modestly raised its price target to $95 from $92 — a small analyst tweak that is unlikely to drive large moves but signals modest incremental confidence. RBC PT Raise
• Neutral Sentiment: Preview coverage notes Incyte is expected to report earnings growth next week, but some commentary suggests the company lacks the setup for a clear beat — adding short-term earnings uncertainty. Earnings Preview
• Neutral Sentiment: Recent analyst and media pieces are debating valuation after mixed returns; these discussions can temper momentum but don't change fundamentals immediately. Valuation Assessment
• Negative Sentiment: Pablo J. Cagnoni, Incyte’s President & Global Head of R&D, sold 18,667 shares under a pre-arranged Rule 10b5-1 plan at about $96.50 (≈$1.8M). The disclosed sale reduced his ownership by ~6.6% and is being cited by traders as a near-term negative signal despite the 10b5-1 context. Insider Sale / SEC Filing

Analyst Ratings Changes

A number of equities analysts recently issued reports on the stock. Jefferies Financial Group lowered shares of Incyte from a "buy" rating to a "hold" rating and dropped their target price for the stock from $120.00 to $94.00 in a research report on Monday, March 16th. UBS Group dropped their target price on shares of Incyte from $104.00 to $94.00 and set a "neutral" rating on the stock in a research report on Wednesday, March 25th. Truist Financial set a $103.00 target price on shares of Incyte in a research report on Wednesday, December 24th. Piper Sandler boosted their target price on shares of Incyte from $102.00 to $110.00 and gave the stock an "overweight" rating in a research report on Friday, February 6th. Finally, Morgan Stanley set a $102.00 price target on shares of Incyte in a report on Wednesday, February 11th. Ten research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Incyte presently has a consensus rating of "Hold" and a consensus target price of $104.89.

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company's research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company's flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.